Spots Global Cancer Trial Database for ASPREE Cancer Endpoints Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ASPREE Cancer Endpoints Study
Official Title: ASPREE Cancer Endpoints Study
Study ID: NCT01968798
Conditions
Study Description
Brief Summary: The ASPREE Cancer Endpoint Study (ACES), an ancillary study of the ASPirin in the Prevention of Events in the Elderly (ASPREE) Study, will allow for the examination of the effect of daily low-dose aspirin (100 mg) compared to placebo, on specific DNA biomarkers and selected specific incident and recurrent cancer and metastases. The establishment of this ACES biobank will allow for the exploration of DNA-related molecular mechanisms of aspirin's protective effect against cancer, cancer associated mortality and metastases, using blood or saliva DNA specimens, urine, and tumor tissue.
Detailed Description: The ASPREE Cancer Endpoint Study (ACES) is an ancillary study of the ASPirin in the Prevention of Events in the Elderly (ASPREE) Study, a 5 year randomized placebo- controlled trial of 100 mg of daily aspirin in 19,000 elderly in Australia and the US to determine whether the benefits of low dose daily aspirin outweigh the bleeding risks. The primary outcome of ASPREE is defined as prolongation of "disability-free life", measured as survival without physical disability or dementia. At present, the primary purpose of ACES is to: 1) collect information about participant cancer screenings, cancer diagnosis, and family history of cancer and to 2) establish a biologic specimen repository (biobank) for DNA and tumor tissue, and urine from the ASPREE large healthy aging population in the US and Australia for future use by ASPREE, NIA and NCI investigators, and academicians from the broader research community. At a time in the future and under separate application, the stored blood or saliva, urine, and tumor tissue, together with other information obtained about these participants (in relation to their health, lifestyle and other circumstances) will be analyzed to address specific questions regarding the association of biomarkers and major health outcomes including cancer.
Eligibility
Minimum Age: 65 Years
Eligible Ages: OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
The University of Alabama at Birmingham, Birmingham, Alabama, United States
Palo Alto Medical Foundation Research Institute, Palo Alto, California, United States
Howard University, Washington, District of Columbia, United States
University of Florida Department of Aging and Geriatrics, Gainesville, Florida, United States
Morehouse School of Medicine, Atlanta, Georgia, United States
Emory/ Atlanta VAMC, Atlanta, Georgia, United States
Georgia Health Sciences University, Augusta, Georgia, United States
Rush Alzheimer's Disease Center, Chicago, Illinois, United States
University of Iowa, Iowa City, Iowa, United States
Kansas University Medical Center, Kansas City, Kansas, United States
Baton Rouge General, Baton Rouge, Louisiana, United States
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
Mary Bird Perkins Our Lady of the Lake Cancer Center, Baton Rouge, Louisiana, United States
Mary Bird Perkins St. Tammany Parish Hospital, Covington, Louisiana, United States
Mary Bird Perkins Terrebonne General Hospital, Houma, Louisiana, United States
LSU Health Sciences- New Orleans, New Orleans, Louisiana, United States
Tulane Medical Center, New Orleans, Louisiana, United States
LSU Health Sciences- Shreveport, Shreveport, Louisiana, United States
University of Michigan, Ann Arbor, Michigan, United States
Wayne State University, Detroit, Michigan, United States
Henry Ford Health System, Detroit, Michigan, United States
Detroit Clinical Research Center, Novi, Michigan, United States
HealthPartners Research Institute, Minneapolis, Minnesota, United States
Phalen Village Clinic, Saint Paul, Minnesota, United States
Central Jersey Medical Center, Elizabeth, New Jersey, United States
New Jersey Medical College, Newark, New Jersey, United States
SUNY Downstate Medical Center, Brooklyn, New York, United States
Winthrop University Hospital, Mineola, New York, United States
Queens Cancer Medical Center, Queens, New York, United States
Wake Forest University Baptist Medical Center, Greensboro, North Carolina, United States
The Brody School of Medicine at ECU, Greenville, North Carolina, United States
Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States
University of Pittsburgh Health Sciences Research Center, Pittsburgh, Pennsylvania, United States
Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, United States
University of Tennessee Health Science Center, Memphis, Tennessee, United States
Meharry Medical College, Nashville, Tennessee, United States
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
University of TX Medical Branch, Galveston, Texas, United States
Regional Academic Health Center, Harlingen, Texas, United States
UT Health Science Center at San Antonio, San Antonio, Texas, United States
Contact Details
Name: Anne Murray, MD, MSc
Affiliation: Berman Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
